Axis-Shield agrees to pay Competitive royalties:
This article was originally published in Clinica
Anglo-Norwegian diagnostics group Axis-Shield has resolved uncertainties over the use of homocysteine testing for vitamin deficiency by agreeing to pay Competitive Technologies royalties. The out-of-court settlement in favour of the US patent holder provides for Axis-Shield to pay out on past and future sales of its kits and those sold by Bio-Rad in the US until the patent expires in 2007. Axis-Shield said most US homocysteine test sales were made through marketing partners that have already arranged licences from Competitive Technologies. The deal should help to stabilise the market and bolster sales of the tests.